AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical…
10 Feb 2026
REGENXBIO receives FDA response for RGX-121 application
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II…
10 Feb 2026
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn. The Takeda-Iambic AI drug discovery…
09 Feb 2026
Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Eli Lilly is acquiring in vivo cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn. Through the agreement, Lilly will gain access to Orna’s new class…
09 Feb 2026
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and the US Food and Drug Administration (FDA) have already set…
09 Feb 2026
Innovent and Lilly to advance new oncology and immunology medicines
Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology. The partnership…
09 Feb 2026
Novartis starts construction on new research facility in San Diego, US
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its drug discovery capabilities. Set to open in 2029, the facility…